These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 25495944)

  • 1. The adverse effects of sorafenib in patients with advanced cancers.
    Li Y; Gao ZH; Qu XJ
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of sorafenib-related adverse events: a clinician's perspective.
    Brose MS; Frenette CT; Keefe SM; Stein SM
    Semin Oncol; 2014 Feb; 41 Suppl 2():S1-S16. PubMed ID: 24576654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Shen CT; Qiu ZL; Luo QY
    Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J; Handkiewicz-Junak D; Jarzab B
    Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib in the treatment of thyroid cancer.
    Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
    Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
    Worden F; Fassnacht M; Shi Y; Hadjieva T; Bonichon F; Gao M; Fugazzola L; Ando Y; Hasegawa Y; Park DJ; Shong YK; Smit JW; Chung J; Kappeler C; Meinhardt G; Schlumberger M; Brose MS
    Endocr Relat Cancer; 2015 Dec; 22(6):877-87. PubMed ID: 26370187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
    Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
    Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib: 10 years after the first pivotal trial.
    Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
    Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
    Walko CM; Grande C
    Semin Oncol; 2014 Feb; 41 Suppl 2():S17-28. PubMed ID: 24576655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
    Yang X; Pan X; Cheng X; Cheng Y; Kuang Y
    Int J Clin Pharm; 2015 Dec; 37(6):1047-56. PubMed ID: 26173936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
    Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
    Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib and thyroid cancer.
    Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
    BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
    Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
    Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
    Jean GW; Mani RM; Jaffry A; Khan SA
    JAMA Oncol; 2016 Apr; 2(4):529-34. PubMed ID: 26847808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
    Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib: targeting multiple tyrosine kinases in cancer.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.